Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031967 · ClinicalTrials.gov registry record · Phase 2
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00031967: Completed Phase 2 study, sponsored by Radiation Therapy Oncology Group.
NCT00031967 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031967, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy. PURPOSE: Randomized phase II trial to determine the effectiveness of combining melatonin with radiation therapy in treating patients who have brain metastases.
Interventions
- RADIATION radiation therapy
- DRUG therapeutic melatonin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-05 |
| Phase | Phase 2 |
What the finished NCT00031967 record still lists
NCT00031967 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00031967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031967 about?
NCT00031967 is a clinical study titled "Melatonin and Radiation Therapy in Treating Patients With Brain Metastases". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy. PURPOSE: Randomized phase II trial to determine the effectiveness of ...
What is the current status of trial NCT00031967?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-05.
What interventions are being tested in trial NCT00031967?
The interventions under investigation include: radiation therapy (RADIATION), therapeutic melatonin (DRUG).
Who is sponsoring clinical trial NCT00031967?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia